125 related articles for article (PubMed ID: 7699233)
1. Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy.
Salerno F; Moser P; Maggi A; Vitaliani G; Benetti G
J Hepatol; 1994 Dec; 21(6):1092-6. PubMed ID: 7699233
[TBL] [Abstract][Full Text] [Related]
2. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.
Morgan MY; Alonso M; Stanger LC
J Hepatol; 1989 Mar; 8(2):208-17. PubMed ID: 2654285
[TBL] [Abstract][Full Text] [Related]
3. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.
Heredia D; Terés J; Orteu N; Rodés J
J Hepatol; 1988 Aug; 7(1):106-10. PubMed ID: 3053887
[TBL] [Abstract][Full Text] [Related]
4. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt.
Riggio O; Balducci G; Ariosto F; Merli M; Pieche U; Pinto G; Tremiterra S; Ziparo V; Capocaccia L
Dig Dis Sci; 1989 Jun; 34(6):823-9. PubMed ID: 2656134
[TBL] [Abstract][Full Text] [Related]
5. Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose.
Riggio O; Balducci G; Ariosto F; Merli M; Tremiterra S; Ziparo V; Capocaccia L
Hepatogastroenterology; 1990 Oct; 37(5):524-7. PubMed ID: 2253931
[TBL] [Abstract][Full Text] [Related]
6. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study.
Morgan MY; Hawley KE; Stambuk D
J Hepatol; 1987 Apr; 4(2):236-44. PubMed ID: 3295020
[TBL] [Abstract][Full Text] [Related]
7. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.
Morgan MY; Hawley KE
Hepatology; 1987; 7(6):1278-84. PubMed ID: 3315932
[TBL] [Abstract][Full Text] [Related]
8. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
Mas A; Rodés J; Sunyer L; Rodrigo L; Planas R; Vargas V; Castells L; Rodríguez-Martínez D; Fernández-Rodríguez C; Coll I; Pardo A;
J Hepatol; 2003 Jan; 38(1):51-8. PubMed ID: 12480560
[TBL] [Abstract][Full Text] [Related]
9. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial.
Heredia D; Caballería J; Arroyo V; Ravelli G; Rodés J
J Hepatol; 1987 Jun; 4(3):293-8. PubMed ID: 3598162
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
Riggio O; Masini A; Efrati C; Nicolao F; Angeloni S; Salvatori FM; Bezzi M; Attili AF; Merli M
J Hepatol; 2005 May; 42(5):674-9. PubMed ID: 15826716
[TBL] [Abstract][Full Text] [Related]
11. Effect of lactitol on blood ammonia response to oral glutamine challenge in cirrhotic patients: evidence for an effect of nonabsorbable disaccharides on small intestine ammonia generation.
Masini A; Efrati C; Merli M; Attili AF; Amodio P; Ceccanti M; Riggio O
Am J Gastroenterol; 1999 Nov; 94(11):3323-7. PubMed ID: 10566738
[TBL] [Abstract][Full Text] [Related]
12. Treatment of porto-systemic encephalopathy with lactitol verus lactulose: a randomized controlled study.
Pai CH; Huang YS; Jeng WC; Chan CY; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jan; 55(1):31-6. PubMed ID: 7712392
[TBL] [Abstract][Full Text] [Related]
13. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose.
Lanthier PL; Morgan MY
Gut; 1985 Apr; 26(4):415-20. PubMed ID: 3979914
[TBL] [Abstract][Full Text] [Related]
14. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
16. [1st use of lactitol in the treatment of porto-systemic encephalopathy].
Bircher J; Bührer M; Franz K; van Velthuijsen JA
Schweiz Med Wochenschr; 1982 Sep; 112(38):1306-7. PubMed ID: 7134954
[TBL] [Abstract][Full Text] [Related]
17. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis.
Cammà C; Fiorello F; Tinè F; Marchesini G; Fabbri A; Pagliaro L
Dig Dis Sci; 1993 May; 38(5):916-22. PubMed ID: 8482191
[TBL] [Abstract][Full Text] [Related]
18. [Lactilol (Importal, 10g in powder made by ZYMA) in the treatment of portal systemic encephalopathy].
Boca M; Duris I; Kolibás E; Kratochvíl'ová E
Vnitr Lek; 1996 Apr; 42(4):234-8. PubMed ID: 8693708
[TBL] [Abstract][Full Text] [Related]
19. [Effects of lactitol on fecal bacterial flora in patients with liver cirrhosis and hepatic encephalopathy].
Tarao K; Tamai S; Ito Y; Okawa S; Hayashi M
Nihon Shokakibyo Gakkai Zasshi; 1995 Jul; 92(7):1037-50. PubMed ID: 7643458
[TBL] [Abstract][Full Text] [Related]
20. Effects of lactitol [correction of lactilol] on hepatic encephalopathy and plasma amino-acid imbalance.
Trovato GM; Catalano D; Carpinteri G; Runcio N; Mazzone O
Recenti Prog Med; 1995; 86(7-8):299-303. PubMed ID: 7569287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
